NCT03630055View on ClinicalTrials.gov

Rivaroxaban Post-Transradial Access for the Prevention of Radial Artery Occlusion

PHASE3RecruitingINTERVENTIONAL
Enrollment

1,800

Participants

Timeline

Start Date

October 3, 2018

Primary Completion Date

December 30, 2025

Study Completion Date

June 30, 2026

Conditions
Radial Artery Occlusion
Interventions
DRUG

Rivaroxaban 15 MG Oral Tablet [Xarelto]

Patients will receive rivaroxaban 15mg orally daily for 7 days following transradial access.

Trial Locations (3)

55905

RECRUITING

Mayo Clinic, Rochester

K7L 2V7

RECRUITING

Kingston Health Sciences Center, Kingston

K1Y4W7

RECRUITING

University of Ottawa Heart Institute, Ottawa

All Listed Sponsors
lead

Ottawa Heart Institute Research Corporation

OTHER